New Drug Development Business
KIYAN PHARMA Co., Ltd. is developing groundbreaking pharmaceuticals using 5-aminolevulinic acid (5-ALA). This initiative is being advanced through close cooperation with domestic and international private companies and public institutions, focusing on developing new drugs for infectious diseases and lifestyle-related diseases.
In particular, collaborative frameworks are being established with research institutions in emerging countries, and future developments are anticipated.
Potential of 5-ALA as a Pharmaceutical
5-ALA plays an important role in mitochondrial function, and mitochondrial dysfunction is believed to cause various diseases. Clinical research on other diseases caused by mitochondrial dysfunction and metabolic disorders is also anticipated.
Licensing Business
In the licensing business, the data obtained from clinical trials conducted by our company are provided to domestic and international pharmaceutical companies for use, expanding this business model.
KIYAN PHARMA Business Overview
Manufacturing 5-ALA for pharmaceuticals, health foods, cosmetics, fertilizers, and feed, according to required quality standards.
The Fukuroi Plant is expanding contract manufacturing of pharmaceutical APIs and intermediates, in addition to 5-ALA.
Supporting consumer beauty and health with supplements and skincare products containing 5-ALA.
Developing and providing products that contribute to animal health maintenance and plant growth promotion using 5-ALA.
Developing new drugs for infectious and lifestyle-related diseases, and expanding licensing businesses.
